Polypeptide drug preparation and preparation method thereof

A technology for pharmaceutical preparations and analogs, applied in the field of GLP-1 analog pharmaceutical preparations, can solve the problems of unachievable drug storage, reduced drug purity, and drug production, and achieve the effects of reducing drug risk, reducing toxic side effects, and reducing degradation.

Active Publication Date: 2015-12-09
QILU PHARMA
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the transportation and storage environment, the preservation of drugs cannot meet the above requirements. Drugs are easily affected by the environme

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide drug preparation and preparation method thereof
  • Polypeptide drug preparation and preparation method thereof
  • Polypeptide drug preparation and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0039] Example 1

[0040] Main medicine / excipient

Example Embodiment

[0041] Example 2

[0042] Main medicine / excipient

Example Embodiment

[0043] Example 3

[0044] Main medicine / excipient

[0045] 2. The amount of liraglutide

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a polypeptide drug preparation with a mixture of citric acid and carbonate as a buffer salt system. The preparation comprises a GLP-1 analog, a buffer agent, an isotonic adjusting agent or a stabilizer and a preservative. The polypeptide drug preparation has the advantages that the pH (potential of hydrogen) of the polypeptide drug preparation is stabilized at a high level with a little amount of buffer salt, meanwhile, the buffer salt can reduce aggregation, degradation, oxidation and sedimentation of the GLP-1 analog, and the stability of the drug preparation is guaranteed in the transportation and storage processes. The invention further discloses a method for preparing the polypeptide drug preparation.

Description

technical field [0001] The present invention belongs to the field of GLP-1 analog pharmaceutical preparations, in particular to GLP-1 analog pharmaceutical preparations prepared in a buffer salt system composed of citrate and carbonate, more specifically to liraglutide pharmaceutical preparations and its preparation method. Background technique [0002] Glucagon-like peptide-1 (GLP-1) is a glucose-dependent incretin hormone secreted by L cells of the terminal jejunum, ileum, and colon. GLP-1 has multiple physiological effects on the human body: first, GLP-1 can act on the β cells of the pancreas, induce insulin secretion in a glucose concentration-dependent manner, improve the sensitivity of β cells, and promote the synthesis of insulin; it has also been found by animal experiments GLP-1 can increase the amount of β cells; GLP-1 can also act on α cells and inhibit the secretion of glucagon. Therefore, GLP-1 can effectively reduce blood sugar without increasing the occurrenc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/26A61K47/12A61K47/02A61P3/10A61P3/04A61P25/28A61P9/00
Inventor 李霞黄河青谭永利张明会
Owner QILU PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products